Preclinical Toxicology Evaluation of Cardiovascular Drugs

Before entering clinical study in humans, innovative cardiovascular drugs must undergo preclinical evaluation to determine their potential toxicity. Ace Therapeutics provides high-quality preclinical toxicology study services to help clients advance development of cardiovascular drugs.

Overview of Toxicity Evaluation of Cardiovascular Drugs

The preclinical toxicity evaluation of new cardiovascular drugs generally includes target organ toxicity, dose-dependent toxicity, exposure-toxicity relationship, and reversibility of toxicity. The main objectives of preclinical toxicity studies of cardiovascular drugs are as follows.

• To identify the target organ of the toxic response to cardiovascular drugs.
• To clarify the toxic response of cardiovascular drugs in experimental animals.
• To determine the range of doses of cardiovascular drugs that produce a toxic response.
• To elucidate the degree of reversibility of cardiovascular drug toxicity.

Fig. 1 Evidence, prevalence and occurrence of safety liabilities relating to the cardiovascular and hepatic systems. (Laverty H, et al. 2011)

Ace Therapeutics has extensive experience in preclinical toxicity studies of cardiovascular drugs. We can provide our clients with the following types of toxicity studies.

Ace Therapeutics specializes in providing outsourcing services for drug development of cardiovascular diseases. With our specialized equipment platform and dedicated research team, we can provide preclinical toxicity studies of cardiovascular drugs according to our clients' needs. If you are interested in our services, please don't hesitate to contact us.

1. Laverty, H.; et al. How can we improve our understanding of cardiovascular safety liabilities to develop safer medicines? Br J Pharmacol. 2011, 163(4):675-693.